Loading patent…
AssigneeRenovo Limited
InventorsMark W. J. Ferguson, Hugh G. Laverty, Nicholas Occleston, Sharon O'Kane, Kerry Nield, Nicholas Goldspink
Estimating the term…
There is provided the use of WNT5A, or a therapeutically effective fragment or derivative thereof, in the preparation of a medicament for use in the prevention, reduction or inhibition of scarring. There is also provided the use of WNT5A, or a therapeutically effective fragment or derivative thereof, in the preparation of a medicament for use in the prevention and/or treatment of a fibrotic disorder. Further aspects relate to methods by which scarring may be prevented, reduced or inhibited, and by which fibrotic disorders may be prevented and/or treated. Therapeutically effective amounts of WNT5A, or its fragments or derivatives, that may be used in the medicaments or methods of the invention are also provided.
The use of WNT5A, or a therapeutically effective fragment or derivative thereof, in the preparation of a medicament for use in the prevention, reduction or inhibition of scarring.
The use of WNT5A, or a therapeutically effective fragment or derivative thereof, in the preparation of a medicament for use in the prevention and/or treatment of a fibrotic disorder.
The use according to any preceding claim, wherein the medicament is an injectable solution comprising WNT5A, or a therapeutically effective fragment or derivative thereof.
The use according to any preceding claim, wherein the medicament is a topical medicament comprising WNT5A, or a therapeutically effective fragment or derivative thereof.
The use according to any preceding claim, wherein the medicament comprises WNT5A of Sequence ID No. 1.
The use according to any preceding claim, wherein the medicament comprises recombinant WNT5A.
The use according to any preceding claim, wherein the therapeutically active fragment of WNT5A comprises a palmitoylated fragment of WNT5A.
The use according to any preceding claim, wherein the therapeutically active derivative of WNT5A, or a fragment thereof, is a peptoid derivative.
The use according to any preceding claim, wherein the WNT5A, or therapeutically active fragment or derivative thereof, is provided in a therapeutically effective amount.
The use according to any preceding claim, wherein the medicament provides more than 0.2 ng WNT5A per linear cm of wound, or cm2 of a wound or fibrotic disorder, over a 24 hour period.
The use of WNT5A, or a therapeutically effective fragment or derivative thereof, in the preparation of a medicament for administering between 0.01 and 33 picomoles of WNT5A, or the fragment or derivative, per linear cm of a wound.
The use of WNT5A, or a therapeutically effective fragment or derivative thereof, in the preparation of a medicament for administering between 0.01 and 33 picomoles of WNT5A, or the fragment or derivative, per cm2 of fibrosis associated with a fibrotic disorder.
The use of WNT5A, or a therapeutically effective fragment or derivative thereof, in the preparation of a medicament for the prevention, reduction or inhibition of scarring, wherein the administration pattern for the medicament comprises administering a therapeutically effective amount of WNT5A, or a fragment or derivative thereof, prior to formation of a wound, and administering a further therapeutically effective amount of WNT5A, or a fragment or derivative thereof, after formation of the wound.
A method of preventing, reducing or inhibiting scarring, the method comprising administering a therapeutically effective amount of WNT5A, or a therapeutically effective fragment or derivative thereof, to a patient in need of such prevention, reduction or inhibition.
A method of preventing and/or treating a fibrotic disorder, the method comprising administering a therapeutically effective amount of WNT5A, or a therapeutically effective fragment or derivative thereof, to a patient in need of such prevention and/or treatment.
Dependencies are inferred from the claim text.